INI-822 (A)
Phase 1Small molecule
INI-822 (A) is one of 4 small molecule programs targeting Metabolic Dysfunction-associated Steatohepatitis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Metabolic Dysfunction-Associated Steatohepatitis
#DrugCompanyPhaseTrials
1ECC4703
EEccogene
Phase 2
Mazdutide
Eli LillyPreclinical
Efimosfermin
BBoston Pharmaceuticals
Phase 2
INI-822 (A)
IInipharm Australia Pty Ltd
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metabolic Dysfunction-associated Steatohepatitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for INI-822 (A). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- IInipharm Australia Pty Ltd